Results 21 to 30 of about 1,577 (196)
Pharmacological ResearchChimeric antigen receptor (CAR)-modified T cell therapy has achieved remarkable efficacy in treating hematological malignancies, but it confronts many challenges in treating solid tumors, such as the immunosuppressive microenvironment of the solid tumors.
Yuankui Zhu +10 more
doaj +2 more sources
<i>trans</i>-Cyclooctene-caged-IL-1β immunocytokine-constructs ligated to unmodified nanobodies allow click-2-release-based control of cytokine activity. [PDF]
RSC Chem BiolImmunocytokines have emerged as a promising modality in cancer therapy, capitalizing on the precision of antibodies to deliver cytokines selectively to tumours.
Barendrecht A +12 more
europepmc +4 more sources
Immunocytokines with activity-on-demand by combination with small molecule inhibitors [PDF]
EMBO Molecular MedicineDose-limiting systemic toxicity constitutes a major impediment to the application of cytokines in cancer therapy. To enhance the therapeutic index, tumor-directed antibody-cytokine fusion proteins, i.e., immunocytokines, are developed for targeting ...
Dafne Müller
doaj +2 more sources
Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity. [PDF]
Mol OncolVon Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Vanmeerbeek I, Sprooten J, Garg AD.
europepmc +2 more sources
Engineering cytokines for cancer immunotherapy: a systematic review
Frontiers in Immunology, 2023 Cytokines are pivotal mediators of cell communication in the tumor microenvironment. Multiple cytokines are involved in the host antitumor response, but the production and function of these cytokines are usually dysregulated during malignant tumor ...
Yong Fu +5 more
doaj +1 more source
Immunocytokines in cancer immunotherapy: opportunities and challenges. [PDF]
Front OncolThe clinical use of cytokines is restricted by dose-limiting toxicities (DLT), short half-life, and rapid renal clearance, which collectively hinder administration at therapeutically effective doses. Cytokines fused to antibodies (antibody–cytokine fusion proteins, or immunocytokines) have emerged as a promising strategy to ...
Wang S, Yao L, Cai J, Gao H, Zhou F.
europepmc +3 more sources
Antibodies, 2012 A number of cytokines have shown beneficial effects in preclinical animal models of cancer and chronic inflammatory diseases. However, cytokine treatment is often associated with severe side effects, which prevent the administration of clinically relevant doses in humans. Immunocytokines are a novel class of biopharmaceuticals, consisting of a cytokine
Katrin L. Gutbrodt, Dario Neri
openaire +2 more sources
mAbs, 2023 There are no effective treatment options for most patients with metastatic colorectal cancer (mCRC). mCRC remains a leading cause of tumor-related death, with a five-year survival rate of only 15%, highlighting the urgent need for novel pharmacological ...
Louis Plüss +10 more
doaj +1 more source
Frontiers in Immunology, 2022 Immunotherapy has emerged as an effective therapeutic approach for several cancer types. However, only a subset of patients exhibits a durable response due in part to immunosuppressive mechanisms that allow tumor cells to evade destruction by immune ...
Ginette S. Santiago-Sánchez +2 more
doaj +1 more source
Frontiers in Immunology, 2021 Management for high-risk neuroblastoma (NBL) has included autologous hematopoietic stem cell transplant (HSCT) and anti-GD2 immunotherapy, but survival remains around 50%.
Paul D. Bates +16 more
doaj +1 more source